🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting in excess of 82 million new cases per year. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This milestone marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Global Access

Based on results published in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study involved over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. Access to a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is viewed as crucial to reduce the burden of the infection for people and to prevent the spread of untreatable gonorrhoea around the world.